Hepatocellular carcinoma: A comprehensive review

World Journal of Hepatology

Volumn 7, Issue 26, 2015, Pages 2648-2663

  Waller, Lisa P ^a   Deshpande, Vrushak ^a   Pyrsopoulos, Nikolaos ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Expansion Milan Criteria; Hepatectomy; Hepatocellular carcinoma; Liver transplantation; Living donor liver transplantation; Mammalian target of rapamycin inhibitors; Milan Criteria; Salvage liver transplantation; Sorafenib; Transarterial chemoembolization; University of California San Francisco Criteria

Indexed keywords

EID: 84962788158     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i26.2648     Document Type: Review

References (114)

1. Byam J, Renz J, Millis JM. Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013; 2: 22-30 [PMID: 24570911]
2. Bravi F, Bosetti C, Tavani A, Gallus S, La Vecchia C. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1413-1421.e1 [PMID: 23660416]
3. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-676 [PMID: 14100514]
4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]
6. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956 [PMID: 2834034]
7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
8. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158-S168 [PMID: 15602165 DOI: 10.1097/00004836-200411003-00008]
9. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803 [PMID: 16817842 DOI: 10.1111/j.1572-0241.2006.00647.x]
10. Ayub A, Ashfaq UA, Haque A. HBV induced HCC: major risk factors from genetic to molecular level. Biomed Res Int 2013; 2013: 810461 [PMID: 23991421]
11. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
12. Sleisenger MH, Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology, diagnosis, management. 9th ed. Philadelphia, PA: Saunders/Elsevier, 2010
13. Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors. World J Gastroenterol 2014; 20: 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945]
14. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-1133 [PMID: 6118576 DOI: 10.1016/S0140-6736(81)90585-7]
15. Cucchetti A, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L, Pinna AD. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. Ann Surg Oncol 2009; 16: 413-422 [PMID: 19034578 DOI: 10.1245/s10434-008-0232-4]
16. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014; 63: 844-855 [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627]
17. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-5107 [PMID: 12910247 DOI: 10.1038/sj.onc.1206557]
18. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233 [PMID: 16603636 DOI: 10.1158/1541-7786.MCR-05-0261]
19. Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int 2014; 2014: 203693 [PMID: 25089265]
20. Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, Zhai W, Cai J, Ling S, Gong Q, Chong Z, Qu Z, Li Q, Liu J, Yang J, Zheng C, Zeng C, Wang HY, Zhang J, Wang SH, Hao L, Dong L, Li W, Sun M, Zou W, Yu C, Li C, Liu G, Jiang L, Xu J, Huang H, Li C, Mi S, Zhang B, Chen B, Zhao W, Hu S, Zhuang SM, Shen Y, Shi S, Brown C, White KP, Chen DS, Chen PJ, Wu CI. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci USA 2011; 108: 12042-12047 [PMID: 21730188 DOI: 10.1073/pnas.1108715108]
21. McKillop IH, Moran DM, Jin X, Koniaris LG. Molecular pathogenesis of hepatocellular carcinoma. J Surg Res 2006; 136: 125-135 [PMID: 17023002 DOI: 10.1016/j.jss.2006.04.013]
22. Luca A, Caruso S, Milazzo M, Mamone G, Marrone G, Miraglia R, Maruzzelli L, Carollo V, Minervini MI, Vizzini G, Gruttadauria S, Gridelli B. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 2010; 20: 898-907 [PMID: 19802612 DOI: 10.1007/s00330-009-1622-0]
23. Bruix J. [Usefulness of the molecular profile in the diagnosis, prognosis and treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2014; 37 Suppl 2: 81-89 [PMID: 25087717 DOI: 10.1016/S0210-5705(14)70074-3]
24. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]
25. European Association for Study of Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48: 599-641 [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021]
26. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
27. Saborido BP, Díaz JC, de Los Galanes SJ, Segurola CL, de Usera MA, Garrido MD, Elola-Olaso AM, Sánz RG, Romero CJ, Garcia García I, González EM. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 2005; 37: 3874-3877 [PMID: 16386569 DOI: 10.1016/j.transproceed.2005.09.169]
28. Salhab M, Canelo R. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther 2011; 7: 463-475 [PMID: 22269411 DOI: 10.4103/0973-1482.92023]
29. Mitchell DG, Bruix J, Sherman M, Sirlin CB. LI-RADS (Liver Imaging Reporting and Data System): summary, discussion, and consensus of the LI-RADS Management Working Group and future directions. Hepatology 2015; 61: 1056-1065 [PMID: 25041904]
30. Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266: 376-382 [PMID: 23362092 DOI: 10.1148/radiol.12121698]
31. Forner A, Bruix J. [Contrast-enhanced ultrasonography in the diagnosis of hepatocellular carcinoma]. Radiologia 2013; 55: 173-174 [PMID: 23228630 DOI: 10.1016/j.rx.2012.10.002]
32. Joo I, Choi BI. New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012; 1: 94-109 [PMID: 24159577 DOI: 10.1159/000342404]
33. Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014; 6: 7-14 [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7]
34. El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut 2011; 60: 992-997 [PMID: 21257990 DOI: 10.1136/gut.2010.230508]
35. Wang NY, Wang C, Li W, Wang GJ, Cui GZ, He H, Zhao HJ. Prognostic value of serum AFP, AFP-L3, and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev 2014; 15: 1539-1544 [PMID: 24641364 DOI: 10.7314/APJCP.2014.15.4.1539]
36. Chan EY, Larson AM, Fix OK, Yeh MM, Levy AE, Bakthavatsalam R, Halldorson JB, Reyes JD, Perkins JD. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14: 956-965 [PMID: 18581511 DOI: 10.1002/lt.21449]
37. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009; 87: 531-537 [PMID: 19307789 DOI: 10.1097/TP.0b013e3181943bee]
38. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, Lai PB, Lam CW, Yeo W, Yu SC. Performance of serum a-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford) 2014; 16: 366-372 [PMID: 23980880 DOI: 10.1111/hpb.12146]
39. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-951 [PMID: 24797281 DOI: 10.1002/lt.23904]
40. Proceedings of the fifth annual meeting of the Japanese Committee for the International Diagnostic Criteria in Psychiatry (JCIDCP). November 2, 1985, Kyoto. Abstracts. Jpn J Psychiatry Neurol 1986; 40: 701-711 [PMID: 3599569]
41. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K, Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007; 13: 1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281]
42. Yoshizumi T, Ikegami T, Yoshiya S, Motomura T, Mano Y, Muto J, Ikeda T, Soejima Y, Shirabe K, Maehara Y. Impact of tumor size, number of tumors and neutrophil-to-lymphocyte ratio in liver transplantation for recurrent hepatocellular carcinoma. Hepatol Res 2013; 43: 709-716 [PMID: 23190306 DOI: 10.1111/hepr.12016]
43. Zheng LY, Yang LL, Li LR, Jing HR, Wang J, Wang QF, Wang Q. [Expressions of TNF-alpha, IL-6, CRP, and MCP-1 in phlegmdamp constitution population detected by multiplexed Luminex assay]. Zhongguo Zhongxiyi Jiehe Zazhi 2013; 33: 920-923 [PMID: 24063213]
44. Pinato DJ, Karamanakos G, Arizumi T, Adjogatse D, Kim YW, Stebbing J, Kudo M, Jang JW, Sharma R. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 2014; 40: 1270-1281 [PMID: 25327965 DOI: 10.1111/apt.12992]
45. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474 [PMID: 20180029]
46. Busuttil RW, Klintmalm GB. Transplantation of the liver. 2nd ed. Philadelphia: Elsevier Saunders, 2005: 1485
47. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-928 [PMID: 2990661]
48. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 2014; 146: 1691-700.e3 [PMID: 24583061]
49. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38: 207-215 [PMID: 12673442 DOI: 10.1007/s005350300038]
50. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10: S115-S120 [PMID: 14762851 DOI: 10.1002/lt.20034]
51. Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, Burra P, Fagiuoli S, Farinati F, Rugge M, D'Amico DF. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004; 239: 150-159 [PMID: 14745321 DOI: 10.1097/01.sla.0000109146.72827.76]
52. Durand F, Belghiti J, Paradis V. Liver transplantation for hepatocellular carcinoma: role of biopsy. Liver Transpl 2007; 13: S17-S23 [PMID: 17969095 DOI: 10.1002/lt.21326]
53. Wong RJ, Devaki P, Nguyen L, Cheung R, Cho-Phan C, Nguyen MH. Increased long-term survival among patients with hepatocellular carcinoma after implementation of Model for Endstage Liver Disease score. Clin Gastroenterol Hepatol 2014; 12: 1534-1540.e1 [PMID: 24361414]
54. Chok KS, Cheung TT, Lo RC, Chu FS, Tsang SH, Chan AC, Sharr WW, Fung JY, Dai WC, Chan SC, Fan ST, Lo CM. Pilot study of high-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients wait-listed for liver transplantation. Liver Transpl 2014; 20: 912-921 [PMID: 24753206 DOI: 10.1002/lt.23892]
55. Cescon M, Cucchetti A, Ravaioli M, Pinna AD. Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate. J Hepatol 2013; 58: 609-618 [PMID: 23041304 DOI: 10.1016/j.jhep.2012.09.021]
56. Ikeguchi M, Urushibara S, Shimoda R, Yamamoto M, Maeta Y, Ashida K. Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. World J Surg Oncol 2014; 12: 210 [PMID: 25022764 DOI: 10.1186/1477-7819-12-210]
57. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25 [PMID: 17103105 DOI: 10.1007/s00270-006-0062-3]
58. DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID, Grant DR, Greig PD. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford) 2011; 13: 24-32 [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228.x]
59. Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, Abdelmaksoud A, Nabeel M. Efficacy and survival analysis of percutaneous radiofrequency versus microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc 2014; 28: 3429-3434 [PMID: 24935203 DOI: 10.1007/s00464-014-3617-4]
60. Llovet JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 2004; 7: 431-441 [PMID: 15527709 DOI: 10.1007/s11938-004-0002-8]
61. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008; 48: 819-827 [PMID: 18688876 DOI: 10.1002/hep.22412]
62. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008; 8: 2547-2557 [PMID: 19032223 DOI: 10.1111/j.1600-6143.2008.02409.x]
63. Bruix J, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rodés J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 1996; 111: 1018-1022 [PMID: 8831597 DOI: 10.1016/S0016-5085(96)70070-7]
64. Simpson KJ, Finlayson ND. Clinical evaluation of liver disease. Baillieres Clin Gastroenterol 1995; 9: 639-659 [PMID: 8903798 DOI: 10.1016/0950-3528(95)90054-3]
65. Cucchetti A, Piscaglia F, Cescon M, Ercolani G, Pinna AD. Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2013; 19: 4106-4118 [PMID: 23864773 DOI: 10.3748/wjg.v19.i26.4106]
66. Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee SG. The Impact of Tumor Size on Long-Term Survival Outcomes After Resection of Solitary Hepatocellular Carcinoma: Single-Institution Experience with 2558 Patients. J Gastrointest Surg 2015; 19: 1281-1290 [PMID: 25956724 DOI: 10.1007/s11605-015-2849-5]
67. Cha C, Fong Y, Jarnagin WR, Blumgart LH, DeMatteo RP. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg 2003; 197: 753-758 [PMID: 14585409 DOI: 10.1016/j.jamcollsurg.2003.07.003]
68. Squires MH, Hanish SI, Fisher SB, Garrett C, Kooby DA, Sarmiento JM, Cardona K, Adams AB, Russell MC, Magliocca JF, Knechtle SJ, Staley CA, Maithel SK. Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. J Surg Oncol 2014; 109: 533-541 [PMID: 24347475 DOI: 10.1002/jso.23531]
69. Hu Z, Zhou J, Li Z, Xiang J, Qian Z, Wu J, Zhang M, Zheng S. Salvage liver transplantation for recurrent hepatocellular carcinoma after liver resection: retrospective study of the Milan and Hangzhou criteria. PLoS One 2014; 9: e87222 [PMID: 24475255 DOI: 10.1371/journal.pone.0087222]
70. Taniguchi M. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry. Clin Transpl 2012: 41-65 [PMID: 23721009]
71. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22 [PMID: 22047762 DOI: 10.1016/S1470-2045(11)70175-9]
72. Alsina AE. Liver transplantation for hepatocellular carcinoma. Cancer Control 2010; 17: 83-86 [PMID: 20404791]
73. Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? Liver Transpl 2007; 13: S27-S35 [PMID: 17969086 DOI: 10.1002/lt.21328]
74. Wiesner R, Lake JR, Freeman RB, Gish RG. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 2006; 12: S85-S87 [PMID: 17123285 DOI: 10.1002/lt.20961]
75. Francoz C, Belghiti J, Castaing D, Chazouillères O, Duclos-Vallée JC, Duvoux C, Lerut J, Le Treut YP, Moreau R, Mandot A, Pageaux G, Samuel D, Thabut D, Valla D, Durand F. Model for end-stage liver disease exceptions in the context of the French model for endstage liver disease score-based liver allocation system. Liver Transpl 2011; 17: 1137-1151 [PMID: 21695771 DOI: 10.1002/lt.22363]
76. Menon KV, Hakeem AR, Heaton ND. Review article: liver transplantation for hepatocellular carcinoma - a critical appraisal of the current worldwide listing criteria. Aliment Pharmacol Ther 2014; 40: 893-902 [PMID: 25155143 DOI: 10.1111/apt.12922]
77. Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry. Liver Transpl 2014; 20: 1045-1056 [PMID: 24838471 DOI: 10.1002/lt.23917]
78. Ahn CS, Moon DB, Lee SG, Hwang S, Kim KH, Ha TY, Song GW, Jung DH, Park GC, Park YH, Park HW, Jung BH, Kang SH. Survival differences between Milan criteria after down-staging and De novo Milan in living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2014; 61: 187-191 [PMID: 24895818]
79. Abdel-Wahab M, Sultan AM, Fathy OM, Salah T, Elshobary MM, Elghawalby NA, Yassen AM, Elsarraf WM, Elsaadany MF, Zalatah K. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma. Hepatogastroenterology 2013; 60: 1847-1853 [PMID: 24719918]
80. Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, Fisher RA. Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes. Transplantation 2014; 98: 100-106 [PMID: 24503764 DOI: 10.1097/01.TP.0000441090.39840.b0]
81. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]
82. Decaens T, Roudot-Thoraval F, Hadni-Bresson S, Meyer C, Gugenheim J, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 2006; 12: 1761-1769 [PMID: 16964590 DOI: 10.1002/lt.20884]
83. Castelli G, Burra P, Giacomin A, Vitale A, Senzolo M, Cillo U, Farinati F. Sorafenib use in the transplant setting. Liver Transpl 2014; 20: 1021-1028 [PMID: 24809799 DOI: 10.1002/lt.23911]
84. Lei JY, Wang WT, Yan LN. "Metroticket" predictor for assessing liver transplantation to treat hepatocellular carcinoma: a singlecenter analysis in mainland China. World J Gastroenterol 2013; 19: 8093-8098 [PMID: 24307805 DOI: 10.3748/wjg.v19.i44.8093]
85. Raj A, McCall J, Gane E. Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol 2011; 55: 1063-1068 [PMID: 21354447 DOI: 10.1016/j.jhep.2011.01.052]
86. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]
87. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85: 1726-1732 [PMID: 18580463 DOI: 10.1097/TP.0b013e31816b67e4]
88. de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist 2007; 12: 1321-1331 [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321]
89. Akamatsu N, Sugawara Y, Kokudo N. Living donor liver transplantation for patients with hepatocellular carcinoma. Liver Cancer 2014; 3: 108-118 [PMID: 24945001 DOI: 10.1159/000343866]
90. Kaido T, Takada Y, Uemoto S. Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010; 16: 538-540 [PMID: 20373466 DOI: 10.1002/lt.22020]
91. Berg CL, Gillespie BW, Merion RM, Brown RS, Abecassis MM, Trotter JF, Fisher RA, Freise CE, Ghobrial RM, Shaked A, Fair JH, Everhart JE. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 2007; 133: 1806-1813 [PMID: 18054553 DOI: 10.1053/j.gastro.2007.09.004]
92. Chen CL, Cheng YF, Yu CY, Ou HY, Tsang LL, Huang TL, Chen TY, Concejero A, Wang CC, Wang SH, Lin TS, Liu YW, Yang CH, Yong CC, Chiu KW, Jawan B, Eng HL, Chan SC, Sharr WW, Lo CM, Tamura S, Sugawara Y, Kokudo N, Lee KW, Yi NJ, Suh KS, Moon DB, Lee SG, Ahn CS, Huang S, Kim KH, Ha TY, Song GW, Jung DH, Park GC, Namkoong JM, Park HW, Park YH, Park CS, Sung KB, Ko GY, Gwon DI, Kaido T, Ogawa K, Fujimoto Y, Ito T, Toniyama K, Mori A, Ogura Y, Uemoto S, Yap AQ, Lin YH, Liu CY, Chiang YC, Lin CC, Shin M, Joh JW, Kabiling C, Hu TH, Kang SH, Jung BH, Choi YR. Living donor liver transplantation: the Asian perspective. Transplantation 2014; 97 Suppl 8: S3 [PMID: 24849827 DOI: 10.1097/TP.0000000000000060]
93. Grant RC, Sandhu L, Dixon PR, Greig PD, Grant DR, McGilvray ID. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant 2013; 27: 140-147 [PMID: 23157398 DOI: 10.1111/ctr.12031]
94. Gish RG, Finn RS, Marrero JA. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2013; 9: 1-24 [PMID: 24872793]
95. Mancuso A, Mazzarelli C, Perricone G, Zavaglia C. Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. J Hepatol 2014; 60: 681 [PMID: 24216445 DOI: 10.1016/j.jhep.2013.10.030]
96. Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012; 57: 821-829 [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014]
97. Roh YN, David Kwon CH, Song S, Shin M, Man Kim J, Kim S, Joh JW, Lee SK. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant 2014; 28: 141-148 [PMID: 24372624 DOI: 10.1111/ctr.12286]
98. Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 2012; 57: 1122-1129 [PMID: 22451120 DOI: 10.1007/s10620-012-2136-1]
99. Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X, Han G. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis. PLoS One 2014; 9: e91124 [PMID: 24651044 DOI: 10.1371/journal.pone.0091124]
100. Chow PK, Poon DY, Khin MW, Singh H, Han HS, Goh AS, Choo SP, Lai HK, Lo RH, Tay KH, Lim TG, Gandhi M, Tan SB, Soo KC. Multicenter phase II study of sequential radioembolizationsorafenib therapy for inoperable hepatocellular carcinoma. PLoS One 2014; 9: e90909 [PMID: 24614178 DOI: 10.1371/journal.pone.0090909]
101. Cholongitas E, Mamou C, Rodríguez-Castro KI, Burra P. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049 [PMID: 24943720 DOI: 10.1111/tri.12372]
102. Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl 2012; 18: 62-69 [PMID: 21964956 DOI: 10.1002/lt.22441]
103. Zhao X, Lu S, Wang M, Wu J, Lin D, Guo Q, Lai W, Zeng D, Li C, Liu Y, Sun L, Yan D, Li N. [A retrospective cohort study regarding the effect of sirolimus-based immunosuppression protocol on the long-term survival of hepatocellular carcinoma patients after liver transplantation]. Zhonghua Waike Zazhi 2014; 52: 245-248 [PMID: 24924566]
104. Morard I, Dumortier J, Spahr L, Hadengue A, Majno P, Morel P, Mentha G, Giostra E. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007; 13: 658-664 [PMID: 17457887 DOI: 10.1002/lt.21116]
105. Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl 2014; 20: 261-269 [PMID: 24376158 DOI: 10.1002/lt.23806]
106. Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer 2010; 10: 190 [PMID: 20459775 DOI: 10.1186/1471-2407-10-190]
107. Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, Zafrani ES, Mallat A, Duvoux C. Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma. Dig Liver Dis 2012; 44: 610-616 [PMID: 22459565 DOI: 10.1016/j.dld.2012.02.005]
108. Menon KV, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]
109. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, Grant DR. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011; 253: 166-172 [PMID: 21294289 DOI: 10.1097/SLA.0b013e31820508f1]
110. Herrero JI, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7: 631-636 [PMID: 11460231 DOI: 10.1053/jlts.2001.25458]
111. Lee S, Ahn C, Ha T, Moon D, Choi K, Song G, Chung D, Park G, Yu Y, Choi N, Kim K, Kim K, Hwang S. Liver transplantation for hepatocellular carcinoma: Korean experience. J Hepatobiliary Pancreat Sci 2010; 17: 539-547 [PMID: 19727542 DOI: 10.1007/s00534-009-0167-6]
112. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD. Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 2008; 8: 1177-1185 [PMID: 18444925 DOI: 10.1111/j.1600-6143.2008.02229.x]
113. Toso C, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2008; 14: 1107-1115 [PMID: 18668667 DOI: 10.1002/lt.21484]
114. Boin IF, Pracucho EM, Rique MC, Reno RR, Robertoni DB, Silva PV, Rosim ET, Soares AB, Escanhoela CA, Leonardi MI, Souza JR, Leonardi LS. Expanded Milan criteria on pathological examination after liver transplantation: analysis of preoperative data. Transplant Proc 2008; 40: 777-779 [PMID: 18455014 DOI: 10.1016/j.transproceed.2008.02.038]